Evidence map›Paper›PMID 34034749›Full record

ArticleJournal of nanobiotechnology2021

Porphyrin-lipid stabilized paclitaxel nanoemulsion for combined photodynamic therapy and chemotherapy.

Enling Chang, Jiachuan Bu, Lili Ding, Jenny W H Lou, Michael S Valic, Miffy H Y Cheng, Véronique Rosilio, Juan Chen, Gang Zheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Enling ChangPrincess Margaret Cancer Centre, University Health Network, PMCRT 5-353, 101 College Street, Toronto, ON, M5G 1L7, Canada.
Jiachuan BuPrincess Margaret Cancer Centre, University Health Network, PMCRT 5-353, 101 College Street, Toronto, ON, M5G 1L7, Canada.
Lili DingPrincess Margaret Cancer Centre, University Health Network, PMCRT 5-353, 101 College Street, Toronto, ON, M5G 1L7, Canada.
Jenny W H LouPrincess Margaret Cancer Centre, University Health Network, PMCRT 5-353, 101 College Street, Toronto, ON, M5G 1L7, Canada.
Michael S ValicPrincess Margaret Cancer Centre, University Health Network, PMCRT 5-353, 101 College Street, Toronto, ON, M5G 1L7, Canada.
Miffy H Y ChengPrincess Margaret Cancer Centre, University Health Network, PMCRT 5-353, 101 College Street, Toronto, ON, M5G 1L7, Canada.
Véronique RosilioInstitut Galien Paris-Saclay, Université Paris-Saclay, CNRS, Châtenay-Malabry, France.
Juan ChenPrincess Margaret Cancer Centre, University Health Network, PMCRT 5-353, 101 College Street, Toronto, ON, M5G 1L7, Canada. juan.chen@uhnresearch.ca.ORCID http://orcid.org/0000-0001-7515-5072
Gang ZhengPrincess Margaret Cancer Centre, University Health Network, PMCRT 5-353, 101 College Street, Toronto, ON, M5G 1L7, Canada. gang.zheng@uhnres.utoronto.ca.ORCID http://orcid.org/0000-0002-0705-7398
University Health Network · CACentre National de la Recherche Scientifique · FRUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPorphyrin-lipids are versatile building blocks that enable cancer theranostics and have been applied to create several multimodal nanoparticle platforms, including liposome-like porphysome (aqueous-core), porphyrin nanodroplet (liquefied gas-core), and ultrasmall porphyrin lipoproteins. Here, we used porphyrin-lipid to stabilize the water/oil interface to create porphyrin-lipid nanoemulsions with paclitaxel loaded in the oil core (PLNE-PTX), facilitating combination photodynamic therapy (PDT) and chemotherapy in one platform.

resultsPTX (3.1 wt%) and porphyrin (18.3 wt%) were loaded efficiently into PLNE-PTX, forming spherical core-shell nanoemulsions with a diameter of 120 nm. PLNE-PTX demonstrated stability in systemic delivery, resulting in high tumor accumulation (~ 5.4 ID %/g) in KB-tumor bearing mice. PLNE-PTX combination therapy inhibited tumor growth (78%) in an additive manner, compared with monotherapy PDT (44%) or chemotherapy (46%) 16 days post-treatment. Furthermore, a fourfold reduced PTX dose (1.8 mg PTX/kg) in PLNE-PTX combination therapy platform demonstrated superior therapeutic efficacy to Taxol at a dose of 7.2 mg PTX/kg, which can reduce side effects. Moreover, the intrinsic fluorescence of PLNE-PTX enabled real-time tracking of nanoparticles to the tumor, which can help inform treatment planning.

conclusionPLNE-PTX combining PDT and chemotherapy in a single platform enables superior anti-tumor effects and holds potential to reduce side effects associated with monotherapy chemotherapy. The inherent imaging modality of PLNE-PTX enables real-time tracking and permits spatial and temporal regulation to improve cancer treatment.

Indexed as

AnimalsCell Line, TumorDrug CarriersDrug TherapyEmulsionsHumansLipidsLiposomesMiceNanoparticlesPaclitaxelPhotochemotherapyPolyethylene GlycolsPorphyrinsTherapeutic UsesXenograft Model Antitumor AssaysDrug CarriersEmulsionsLipidsLiposomesPaclitaxelPolyethylene GlycolsPorphyrinsTherapeutic UsesCancer therapyChemotherapyDrug deliveryNanoparticlePaclitaxelPhotodynamic therapyPorphyrin

Identifiers

PMID34034749
PMCPMC8147067
OpenAlexW3165303653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.